New Business Opportunities in Bio/Pharma,
Medical Devices & Diagnostics
January 2017 |
Welcome to the January 2017 issue of PharmSource PERISCOPE
This monthly e-newsletter provides valuable insight to sales and marketing professionals who sell goods and services to bio/pharma, medical device or diagnostic companies. It helps you recognize new business opportunities and overcome sales obstacles.
Enjoy the January issue, and Happy New Year!
PharmSource Lead Sheet
Summary of Global Clinical Pipeline Activity
Lead Type | December 2016 | CY 2016 |
---|---|---|
Early Development | 88 | 1384 |
Late Development | 93 | 1397 |
Biologic | 94 | 1244 |
Small Molecule | 207 | 3027 |
Parenteral | 92 | 1340 |
Oral | 85 | 1176 |
New Financings | 70 | 924 |
Total Drug Leads | 376 | 4477 |
Total Device & Diagnostic Leads |
137 | 1681 |
*Total leads include acquisitions/alliances, company acquisition/alliances and events.
Pipeline Tip
Adynxx plans to initiate a Phase II trial with AYX1 for the prevention of chronic pain after major surgery:
- Therapeutic Area: Analgesic – Non-narcotic
- Dosage Form: Parenteral
- API: Nucleic acid – DNA
Get deeper information about the likely upcoming needs of Adynxx, its pipeline, contacts and more in the PharmSource Lead Sheet. If you’re not yet a subscriber, click here to learn more.
CRISPR: Gene Therapy 2.0
by Mahdia Hashimy, Research Analyst
It looks like 2017 will be an exciting year for the Biotech industry. One development that has caught much attention is the new generation of gene therapy, the CRISPR-Cas9 genome editing tool that with cautious optimism is expected to start a new wave of faster, more accurate treatment for monogenetic diseases through DNA modification.
With the CRISPR-Cas9, (Clustered Regularly Interspaced Short Palindromic Repeats) editing tool, scientists are able to accurately alter a DNA sequence, removing and replacing faulty DNA, and have the potential to treat a range of genetic medical conditions. With around 5,000 inherited disorders caused by… read on
Follow the Money to
Bio/Pharmaceutical Opportunities
Spotlight on Clearside Biomedical, Inc.
Clearside Biomedical is a U.S. public bio/pharmaceutical company that develops and commercializes therapeutic products using an ocular microinjection platform to target the individual compartments of the eye. They plan to raise $36 million in a secondary public offering.
What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to continue early-stage R&D and to complete… read on
Follow the Money to
Medical Device & Diagnostic Opportunities
Spotlight on Femasys, Inc.
Femasys is a U.S. private company that develops and manufactures medical devices for the treatment of infertility and cervical cancer. They raised $40 million in a completion of a Series C venture capital investment.
What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to support the pivotal trial of the FemBloc… read on
How much longer is the boom in the CDMO and CRO business likely to continue?
PharmSource Lead Sheet
The PharmSource Lead Sheet is the industry’s definitive source for identifying targeted new business opportunities in bio/pharmaceutical companies around the world. Our dedicated research team knows how and where to find fresh, targeted leads, and we have the contact information you need to start the sales process.
Don’t be the last to learn about the latest business development opportunities. If you’re not already using the Lead Sheet, contact us today to schedule a complimentary test-drive.
See for yourself how this resource can be a vital tool for building your brand and growing your market share.
To request a test-drive today, contact Nathaniel Celentano at nathaniel@pharmsource.com / 1-703-383-4903, ext. 112 (ET USA).